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Abstract: Glutamatergic projections from the cortex and dopaminergic projections from the substantia
nigra or ventral tegmental area synapse on dendritic spines of specific GABAergic medium spiny
neurons (MSNs) in the striatum. Direct pathway MSNs (dMSNs) are positively coupled to protein
kinase A (PKA) signaling and activation of these neurons enhance specific motor programs whereas
indirect pathway MSNs (iMSNs) are negatively coupled to PKA and inhibit competing motor programs.
An imbalance in the activity of these two programs is observed following increased dopamine signaling
associated with exposure to psychostimulant drugs of abuse. Alterations in MSN signaling are
mediated by changes in MSN protein post-translational modifications, including phosphorylation.
Whereas direct changes in specific kinases, such as PKA, regulate different effects observed in the
two MSN populations, alterations in the specific activity of serine/threonine phosphatases, such as
protein phosphatase 1 (PP1) are less well known. This lack of knowledge is due, in part, to unknown,
cell-specific changes in PP1 targeting proteins. Spinophilin is the major PP1-targeting protein in
striatal postsynaptic densities. Using proteomics and immunoblotting approaches along with a novel
transgenic mouse expressing hemagglutainin (HA)-tagged spinophilin in dMSNs and iMSNs, we have
uncovered cell-specific regulation of the spinophilin interactome following a sensitizing regimen of
amphetamine. These data suggest regulation of spinophilin interactions in specific MSN cell types
and may give novel insight into putative cell-specific, phosphatase-dependent signaling pathways
associated with psychostimulants.
Keywords: amphetamine; spinophilin; protein phosphatase-1; dopamine; striatum
1. Introduction
Psychostimulant drug abuse is becoming increasingly popular and costly globally [1,2].
Psychostimulant drugs of abuse, such as methamphetamine, amphetamine, and cocaine, have been
associated with dopamine (DA) receptor dysfunction, improper synaptic transmission, and other
neuronal perturbations that may contribute to addiction pathology [3–8]. Psychostimulants drive
hyper-dopaminergic signaling within the striatum by increasing DA concentrations and enhancing
DA transmission [9–14]. When low doses of psychostimulants are administered chronically, response
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to the drug also increases, causing progressive potentiation of motor programs, a process known
as behavioral sensitization [15,16]. Thus, DA plays a critical role in basal ganglia regulated motor
programs [17–22].
The striatum is the largest structure within the basal ganglia and has been shown to play a role in
disease states, such as Huntington and Parkinson Disease (HD and PD, respectively), and neurological
disorders like obsessive-compulsive disorder (OCD) and drug addiction/abuse [23–28]. The striatum
is divided into two main regions: The dorsal striatum (dStr) and the ventral striatum (vStr), which
includes the nucleus accumbens (NAc) and the olfactory tubercle (OT). The dStr is innervated
by dopaminergic projections arising from the substantia nigra (SN) and has been functionally
described as a modulator of motor domains specifically involving action selection and initiation [29,30].
The vStr is innervated by dopaminergic projections from the ventral tegmental area (VTA) and is
involved in mediating reward and motivational domains [31–33]. However, studies also suggest
that there is significant overlap in motor and reward functional domains within the striatum [34,35].
Approximately 90–95% of the neuronal populations within the striatum are gamma-aminobutyric acid
(GABA)-ergic medium spiny neurons (MSNs). There are two MSN subtypes within the striatum that
are characteristically distinct based on physiological and structural properties, as well as differential
expression of DA receptor subtypes and neuropeptide hormones [36–38]. Differential expression
of DA receptors allows for differential signaling within striatal MSNs. Studies have shown that
characteristics and behaviors associated with striatal specific pathological maladies can occur when
there is an imbalance in the activity and/or signaling between the two MSN classes [14,39–41]. Direct
pathway MSNs (dMSNs) contain the D1 class of DA receptors, which are positively coupled to PKA
signaling. Activation of dMSNs enhances basal ganglia related motor programs. Conversely, indirect
pathway MSNs (iMSNs) contain the D2 class of DA receptors, which are negatively coupled to PKA
signaling. Activation of iMSNs inhibits inappropriate basal ganglia regulated motor function [42–45].
Thus, the opposing functions of dMSNs and iMSNs are, in part, regulated by post-synaptic responses
to DA-dependent signaling.
In the post-synaptic density (PSD) of MSNs, reversible protein phosphorylation is facilitated
by kinase and phosphatase activity, contributing to competent neuronal signaling, communication,
and synaptic plasticity. To achieve proper signaling, serine/threonine kinases phosphorylate
substrates utilizing specific consensus sites; however, serine/threonine phosphatases, such as protein
phosphatase 1 (PP1), associate with targeting proteins to attain specificity [46,47]. The most abundant
targeting protein for PP1 in the PSD is spinophilin [46,48–50]. Spinophilin acts as a scaffolding protein
by targeting PP1 to specific substrates; however, spinophilin can also inhibit the activity of PP1,
driving changes in synaptic strength and plasticity [48,51–53]. Furthermore, spinophilin is enriched
in the PSD of dendritic spines, and is essential for proper dendritic spine function by regulation of
critical dendrite properties [48,54–56]. Changes in MSN dendritic spine density and morphology,
perturbations in synaptic transmission and concomitant aberrant dopaminergic signaling are all
major contributors to striatal disease states like drug addiction and myriad others [23,26,27,31,57].
In addition, psychostimulant administration, which drives hyper-dopaminergic responses was shown
to increase spinophilin expression in the striatum [58,59]. As stated above, alterations in DA levels
will regulate DA receptor activity and downstream activation of kinases, such as PKA. Spinophilin is
phosphorylated by PKA and PKA phosphorylation of spinophilin is known to decrease its binding to
F-actin [49,60]. DA depletion, which decreases DA terminals in the striatum, modulates spinophilin
interactions within the striatum. Specifically, there were increases in spinophilin binding to PP1;
however, the interactions of spinophilin with a plurality of spinophilin-associated proteins (SpAPs)
were decreased [61,62]. We have shown that whole-body spinophilin knockout (KO) mice do not
undergo d-amphetamine-induced behavioral sensitization [63]. However, how excessive DA signaling,
as occurs following psychostimulant sensitization, modulates spinophilin interactions is unclear. Here
we show that in contrast to DA depletion, amphetamine sensitization increases a majority of striatal
spinophilin interactions. Moreover, in our preliminary studies using a novel transgenic mouse line
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that allows for Cre-dependent expression of an hemagglutinin (HA)-tagged form of spinophilin,
we observed both pan-MSN and putative cell-specific alterations in spinophilin interactions following
amphetamine treatment. Together, these data delineate alterations in spinophilin interactions that may
contribute to psychostimulant-induced pathologies.
2. Materials and Methods
2.1. Animals—HA Spinophilin Mice Generation
All animal studies were performed in accordance with the Guide for the Care and Use of
Laboratory Animals as disseminated by the U.S. National Institutes of Health and were approved by
Indiana University-Purdue University School of Science Animal Care and Use Committees (Approval
#SC270R). A human, HA-tagged spinophilin construct [62] containing a P2A sequence and the
mNeptune 3 protein were assembled into the pBigT vector between the ClaI and SacI restriction
sites (Figure 1A). Gene files were assembled in SnapGene (GSL Biotech, Chicago, IL, USA) or Vector
NTI (ThermoFisher Scientific, Waltham, MA, USA). The insert was then subcloned into the AscI/PacI
sites on the pROSA26.PA vector (Figure 1B) for generation of targeted embryonic stem cells (ES)
cells. pROSA26.PA vector was linearized with AscI and injected into SV129 ES cells by the Vanderbilt
Transgenic Mouse/ESC Shared Resource. These ES cells were transferred into pseudo-pregnant
C57Bl6/J females and chimeric pups were born from two of these clones (2D4 and 2E12). Chimeras
were transferred from the Vanderbilt Transgenic Mouse/ESC Shared Resource to the mouse colony
at IUPUI. One clone was maintained in house. Mice were backcrossed at least six generations onto
a C57Bl6/J background. Mice were subsequently crossed with either the Drd1a-Cre line or onto an
A2A-Cre line [64,65] that were on the C57Bl6/J background. For proteomics, mice expressing a single
copy of spinophilin knocked-in to the ROSA locus were used. For immunoblotting, mice expressing
HA-spinophilin knocked into one or both copies of the ROSA locus were used. For those expressing a
single copy of spinophilin, the other ROSA allele was either WT or had a flox-stop tdTomato reporter
sequence inserted (Jackson laboratories Stock #007914, Bar Harbor, ME, USA).
2.2. Animals—Proteomics Studies
Adult male and female mice were used for the proteomics studies (Table 1).
Table 1. Animals used for proteomics studies. Sex, genotype, weight of animals used for proteomics studies.
Eartag Sex Condition Genotype Cre InitialWeight
Final
Weight Birth Date Sacrifice Date
2450 M Saline Het/Cre+ D1 23.8 25.0 31 January 2018 30 March 2018
2452 M Treated Het/Cre+ D1 22.4 23 31 January 2018 30 March 2018
2453 M Treated tdHet/HA-Het/Cre+ D1 23.0 23.3 31 January 2018 30 March 2018
2454 M Saline Het/Cre+ D1 22.3 22.8 31 January 2018 30 March 2018
2390 F Saline Het/Cre+ A2A 22.9 22.8 3 January 2018 30 March 2018
2393 F Treated Het/Cre+ A2A 20.9 20.8 3 January 2018 30 March 2018
2443 F Saline Het/Cre+ D1 21.5 21.7 29 January 2018 30 March 2018
2444 F Treated Het/Cre+ D1 19.6 19.8 29 January 2018 30 March 2018
2.3. Animals—Immunoblotting Studies
Four male or female P85–P120 mice were used for immunoblotting analysis of HA spinophilin.
In addition, one adult P90 WT and one adult spinophilin KO mouse [63,66] were used to validate a
subset of spinophilin interactions.
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Figure 1. Generation and characterization of Cre-expressing, HA-tagged human spinophilin mice.
(A) A construct containing DNA encoding HA-tagged human spinophilin with a P2A sequence
and mNeptune3 fluorescent protein was cloned into the pBIGT vector that contains a floxed-stop
sequence. (B) The construct encoding the floxed-stop sequence and the HA-spinophilin-P2A-mNeptune
3 sequence was subcloned into the ROSA targeting vector pROSA_26.PA. (C) The modified
ROSA vector was used for generation of the targeted transgenic mice. (D) Striatal cells were
transfected without or with HA-tagged human spinophilin. Lysates were immunoprecipitated with
either an HA or spinophilin antibody and immunoblotted with an HA antibody or a spinophilin
antibody. HA-spinophilin was selectively detected when it was overexpressed. (E) Mice express
HA-tagged spinophilin upon crossing with Cre recombinase expressed in the direct pathway (D1)
or indirect pathway (A2A) medium spiny neurons. (F) Spinophilin and protein phosphatase 1
immunoblots of inputs and HA-immunoprecipitates from HA spinophilin mice crossed with D1
or A2A Cre-recombinase-expressing mice. (G) Mice expressing HA-spinophilin had non-significant
increases in total spinophilin expression.
2.4. d-Amphetamine Sensitization
Mice received daily intraperitoneal (i.p) injections of d-amphetamine at 3.0 mg/kg (Sigma-Aldrich,
St. Louis, MO, USA) or saline (10 mL/kg) for five consecutive days. Mice were then sacrificed and
striata dissected 72 h after the last injection.
2.5. Brain Tissue Lysis
Mouse striatum (including both dorsal and ventral (accumbens) striatum or olfactory tubercle)
was homogenized and sonicated in 1 mL in a low-ionic strength Tris buffer containing 20 mM 1M Tris,
10 mM DTT, 2 mM 0.5 M EDTA, 10% Triton X-100, 1% protease inhibitor cocktail (Bimake, Houston,
TX, USA), phosphatase inhibitors (20 mM sodium fluoride, 20 mM sodium orthovanadate, 20 mM
β-glycerophosphate, and 10 mM sodium pyrophosphate; Sigma-Aldrich or ThermoFisher Scientific
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(Waltham, MA, USA)). Homogenates were incubated for 15 min at 4 ◦C and then centrifuged at
13,600× g for 10 min. The cleared lysate was mixed with Laemmli sample buffer to generate the input
or subjected to immunoprecipitation.
2.6. Transfections
Mouse STHdhQ7/7 striatal cell line (a kind gift from Dr. Gunnar Kwakye, Oberlin College,
Oberlin, OH, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) that contained 10%
fetal bovine serum, 1% GlutaMAXTM (ThermoFisher Scientific), 400 µg/mL G418-Sulfate (Geneticin)
(ThermoFisher Scientific), 100 U/mL penicillin, and 100 µg/mL streptomycin. Culture plates were
incubated at a constant 33 ◦C and 5% CO2 in myTemp Mini CO2 digital incubator (Benchmark Scientific;
Edison, NJ, USA). Cells were transfected overnight with 2 µg of HA-tagged human spinophilin and
PolyJet reagent (SignaGen Laboratories, Gaithersburg, MD, USA) per the manufacturers’ instructions.
Cells were lysed in the low-ionic strength Tris buffer.
2.7. Immunoprecipitations
Striatal lysates were immunoprecipitated with an HA-epitope antibody or spinophilin antibody.
3 µg of goat HA polyclonal antibody (Bethyl Laboratories, Montgomery, TX, USA, A190-238A) or
5 µg goat spinophilin polyclonal antibody (Santa Cruz Biotechnology, Dallas, TX, USA, SC14774)
were incubated at 4 ◦C with 750–800 µL (75–80%) of total striatal lysate overnight. Striatal cell lysates
were immunoprecipitated with 1.6 µg of a sheep spinophilin antibody (ThermoFisher Scientific).
The following day, protein G magnetic beads (DynaBeads, ThermoFisher Scientific) were added,
and the mixture was incubated for 2 h. Beads were washed three times by magnetic separation in an
immunoprecipitation wash buffer (50 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.5% (v/v) Triton X-100).
For immunoblotting, beads were resuspended in 2X sample buffer. For Tandem Mass Tag (TMT)
labeling, beads were subsequently washed three times in PBS by centrifugation. Washed beads were
submitted for tryptic digestion and each sample was labeled with an isobaric tandem mass tag to allow
for quantitation.
2.8. TMT Labeling and Mass Spectrometry
Following washes, immunoprecipitated samples on beads were reduced with 5 mM
tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and alkylated with 10 mM chloroacetamide
(CAM). Beads were then incubated with Trypsin Gold (Promega) at 37 ◦C overnight. Digested samples
were cleaned up using a Waters Sep-Pak C18 plate per manufacturer’s instructions.
For TMT labeling, tryptic peptides from each individual condition were labeled with eight
different isobaric TMT tags using 8 of a 10-plex TMT kit (ThermoFisherScientific) and following
manufacturer’s instructions. Following individual labeling, samples were mixed and separated by
HPLC and subjected to mass spectrometry.
For HPLC and mass spectrometry analysis, digested peptides were loaded onto an Acclaim
PepMap C18 trapping column and eluted on a PepMap C18 analytical column with a linear gradient
from 3% to 35% acetonitrile (in water with 0.1% formic acid) over 120 min in-line with an Orbitrap
Fusion Lumos Mass Spectrometer (ThermoFisher Scientific). Raw files generated from the run were
analyzed using Thermo Proteome Discoverer (PD) 2.2. SEQUEST HT (as a node in PD 2.2) was utilized
to perform database searches as previously described [67] with a few modifications: Trypsin digestion,
two maximum missed cleavages, precursor mass tolerance of 10 ppm, fragment mass tolerance of
0.8 Da, fixed modifications of +57.021 Da on cysteine, +229.163 on lysines and peptide N-terminii, and a
variable modification of +15.995 Da on methionine. The spectral false discovery rate (FDR) was set to
≤1% as previously described [68]. The FASTA database used was a mouse proteome downloaded from
Uniprot on January 9, 2017 with the addition of 72 common contaminants. Results and quantitative
information from the TMT were exported to an Excel Spreadsheet (Tables S1 and S2, Microsoft, Seattle,
WA, USA) and tables were generated from these data. A total intensity from the TMT labels, derived
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from all of the tryptic peptides matching to a specific protein, is given. These intensity data were
used for comparing the abundance of different proteins. Examples of these TMT peaks are shown in
Figures S2–S5.
2.9. Immunoblotting
Striatal lysates were immunoblotted with the appropriate primary antibody (see below).
For protein detection the following primary antibodies were used: HA rabbit antibody (Bethyl
Laboratories A190-208A), mouse Clathrin Heavy Chain monoclonal antibody (Santa Cruz, CA,
USA, sc12734), rabbit SAP102 monoclonal antibody (Cell Signaling Technology, Danvers, MA,
USA; 47421S), rabbit SNIP/p140Cap (SRCIN1) polyclonal antibody (Cell Signaling Technology
3757) and goat or sheep spinophilin polyclonal antibody (as above) or rabbit spinophilin antibody
(Cell Signaling Technology 14136S). Antibody dilutions were used at 1:500–1:2000 for immunoblotting.
Following overnight incubation at 4 ◦C, the following secondary antibodies were used for fluorescence
detection: Donkey anti-rabbit (H+L) Alexa Fluor 790 (Jackson Immunoresearch, West Grove, PA, USA
#711-655-152, 1:50,000 dilution), Donkey anti Goat Alexa Fluor 680 (ThermoFisher Scientific A21084;
1:10,000 dilution), Donkey anti-mouse (H+L) Alexa Fluor 680 (ThermoFisher Scientific, A10038; 1:10,000
dilution), Donkey anti-mouse (H+L) Alexa Fluor 790 (Jackson Immunoresearch #715-655-151, 1:50,000).
Imaging was performed on an Odyssey CLx system (LI-COR Biosciences, Lincoln, NE, USA).
2.10. Pathway Analysis
Proteins that were increased in HA-spinophilin immunoprecipitates isolated from amphetamine
treated animals were analyzed using the Database for Annotation, Visualization and Integrated
Discovery (DAVID) Bioinformatics Resource (version 6.8; https://david.ncifcrf.gov/, National Cancer
Instutitue at Frederick, MD, USA [69,70]). Proteins were analyzed using the Kyoto encyclopedia of
genes and genomes (KEGG) and gene ontology (GO) pathway databases.
2.11. Statistics
To compare saline to amphetamine treatment across all groups combined, a t-test was performed
to compare spinophilin abundance in the amphetamine vs. saline treated samples. A non-adjusted
t-test and a t-test adjusted for multiple comparisons (using the Holm-Sidak method) were performed
to compare the abundance of the proteins isolated from amphetamine compared to saline-treated
samples (both non-normalized (Table S1) and normalized (Table S2). For normalization for PCA
analysis and protein abundance, we divide the abundance of the individual protein in the individual
sample by the total peptide or total spinophilin abundance detected in that sample. Given that there
was an N of 1 in some of the sub-categories (e.g., A2A male and D1 female) the study was not powered
nor intended to make statistical conclusions and these results are a qualitative display of sex- and
cell-specific protein interactions.
3. Results
3.1. Generation of HA-Tagged Spinophilin Mice
We created constructs that encoded HA-tagged human spinophilin [62] along with a P2A sequence
and a far-red fluorescent protein (mNeptune3 [71]). Mice were generated from these constructs
by the Vanderbilt Transgenic Mouse/ESC Shared Resource (see methods). When crossed with
Cre-expressing mice, these animals express HA-tagged human spinophilin under control of the
ROSA promoter (Figure 1C). When crossed with mice expressing Cre recombinase under control of
the Drd1a gene or the Adora2a gene, we were able to detect HA signal in HA immunoprecipitates by
immunoblotting (Figure 1D,E). Furthermore, we were able to detect known spinophilin interacting
proteins PP1 and GluN2B [48,50,72,73] in the HA immunoprecipitates isolated from Cre-expressing
lines (Figure 1E). Less PP1 and GluN2B co-precipitated from the Cre-negative animals (Figure 1E).
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Moreover, a spinophilin antibody also detected a band in the HA immunoprecipitates isolated from
Cre-expressing, but not Cre-negative mice (Figure 1D,F). Of note, we detected a doublet in the
HA-immunoprecipitates when immunoblotting for spinophilin isolated from the HA-spinophilin
expressing mice, as well as a striatal cell line transfected with an HA-spinophilin construct (Figure 1F).
This is not surprising as spinophilin is thought to homo-dimerize and this suggests that the human
HA-spinophilin is complexing with the endogenous, mouse spinophilin. However, there was no
significant difference in the amount of total spinophilin in the mice expressing HA-spinophilin,
suggesting a low overexpression of spinophilin (Figure 1G). Moreover, given the low expression of
epitope tagged spinophilin and fluorescent protein, we were unable to detect either HA-tagged protein
or fluorescent protein by immunohistochemistry (data not shown).
3.2. Amphetamine Modulates Spinophilin Expression and Interactions
DA signaling within the striatum modulates MSN activity and signaling [74,75]. Amphetamine
increases the release of DA at dopaminergic terminals synapsing on MSNs [9,11,12]. Our previous
studies show that DA depletion alters the spinophilin interactome [62] and that spinophilin KO
mice do not undergo amphetamine-induced locomotor sensitization [63]. However, how spinophilin
normally contributes to synaptic changes associated with amphetamine-dependent striatal changes
is unclear. As spinophilin targets PP1 to regulate synaptic protein phosphorylation, in order to
identify potential spinophilin-dependent synaptic protein targets that are regulated by spinophilin
following amphetamine sensitization, we utilized our HA-tagged spinophilin mice (Figure 1) to
measure spinophilin interactions in saline- or amphetamine-treated mice expressing spinophilin in D1
DA or A2A adenosine-receptor containing neurons of the striatum. Mice were injected with 3 mg/kg
amphetamine every day for five days and sacrificed 72 h after the final amphetamine treatment. Striatal
lysates were immunoprecipitated with an HA antibody, digested with trypsin, labeled with TMTs,
and analyzed by mass spectrometry (Figure 2A). A total TMT abundance for spinophilin was detected
in all conditions. As human and mouse spinophilin differ by fewer than 30 amino acids (Figure S1)
and as spinophilin homo-dimerizes we searched only the mouse database. Forty-eight spectral
counts matching spinophilin were detected across all eight samples. While the human construct and
mouse spinophilin are highly homologous, there are 28 (out of 817) different amino acids between
the two species that lead to the generation of ~12 different potential tryptic fragments (Figure S1).
We validated two MS/MS spectra generated from tryptic peptides that were predicted to be different
between mouse and human spinophilin (Figures S2–S5). This further validates the expression of our
HA-tagged human spinophilin construct. Based on the unnormalized abundance of the TMT tag from
the different samples, we observed more spinophilin in the amphetamine-treated compared to control
treated samples (Figure 2B). A principal component analysis from all proteins (1454) of the individual
samples, normalized to total peptide amount, revealed that 46.2% of the total variability is due to
amphetamine treatment (Figure 2C). We next evaluated changes in the TMT tag abundance ratios
(amphetamine/saline) of the spinophilin interacting proteins. For this, we eliminated all contaminant
proteins and only included those proteins detected in all eight samples (e.g., with all eight tags).
This led to the detection of 984 total proteins in the HA-spinophilin immunoprecipitates (Table S1).
We plotted these unnormalized values using a volcano plot with Log2 abundance ratio on the X-axis
and −log10 p-value (t-test, non-adjusted) on the Y-axis (Figure 2D). All but two proteins showed an
increased abundance in spinophilin immunoprecipitates isolated from amphetamine compared to
saline treated samples.
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Figure 2. Quantitation of spinophilin complexes isolated from dMSNs and iMSNs using tandem
mass tag (TMT) analysis. (A) Striatal lysates isolated from male or female mice expressing HA
spinophilin under the control of D1 or A2A promoters and treated with saline or amphetamine were
immunoprecipitated with an HA antibody, digested with trypsin, labelled with eight different TMT
tags, mixed and analyzed by mass spectrometry (MS/MS). (B) A higher intensity of TMT reporter
abundance matching spinophilin was observed in amphetamine-treated compared to saline treated
animals (t-test; * p < 0.05). (C) Principal component analysis of individual samples normalized to
total peptide amount within each sample. (D) A volcano plot showing a majority of the protein have
increased abundance in HA immunoprecipitates isolated from amphetamine treated animals.
3.3. Regulation of Spinophilin Interactions by Amphetamine
Given that spinophilin abundance was increased in immunoprecipitates isolated from
amphetamine treatment compared to saline-treated samples, to determine if the increased association
of spinophilin with interacting proteins was due exclusively to increased spinophilin levels,
we normalized the abundance of each individual interacting protein to the abundance of spinophilin
in the corresponding sample (Table S2A). Moreover, in Table S2, we show only those proteins that
contained at least eight peptide spectral matches (PSMs) as these would average 2 PSMs per condition.
We detected 423 total proteins across all conditions that met these criteria. Of these proteins, 134 were
unchanged (Log2 ratio −0.5 to +0.5), three had a decreased association (<Log2 Ratio −0.5), and 286
had an increased association (>Log2 Ratio +0.5) with spinophilin. Those proteins with a decreased
interaction ratio of <−0.5 and increased interaction ratio of >1.0 are shown in Table 2. We performed a
second PCA analysis of the data normalized to spinophilin for those peptides having eight PSMs or
more (Figure 3A). This mode of analysis decreased the variability within the amphetamine treatment
group but increased the variability in the saline treatment group. We plotted these normalized values
using a volcano plot with Log2 abundance ratio on the X-axis and−log10 P-value (t-test, non-adjusted)
on the Y-axis (Figure 3B). Therefore, even when normalized to spinophilin there is a higher number
of proteins with an enhanced association with spinophilin compared to a decreased or no change
in association.
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Figure 3. Greater abundance of spinophilin interacting proteins in amphetamine-treated animals occurs
across both sexes and cell types. (A) Principal component analysis of individual samples normalized to
spinophilin abundance within each sample and filtered for eight or more PSMs. (B) A volcano plot
showing a majority of the proteins have increased abundance in HA immunoprecipitates isolated
from amphetamine treated animals when normalized to the amphetamine-dependent increase in
spinophilin abundance. (C) A plot of the abundance of spinophilin interacting proteins isolated from
male, D1 Cre expressing animals and normalized for spinophilin expression (Table S2) and quantified
from treated (Y-axis) or control (X-axis) samples. Left panel shows mean± standard deviation, the right
panel just shows the mean of the two values. (D) A plot of the abundance of spinophilin interacting
proteins isolated from female, D1 Cre expressing animals and normalized for spinophilin expression
(Table S2) and quantified from treated (Y-axis) or control (X-axis) samples. (E) A plot of the abundance
of spinophilin interacting proteins isolated from female, A2A-Cre expressing animals and normalized
for spinophilin expression (Table S2) and quantified from treated (Y-axis) or control (X-axis) samples.
We next evaluated the spinophilin interacting proteins from the different cell types and sexes.
It is important to note that evaluation of these sub-categories (sex and genotype) are qualitative and
no statistical inference can be made; however, these preliminary studies denote the importance of
evaluating different sexes and cell types. We plotted the abundance of the amphetamine treated
samples on the Y-axis and the abundance of the saline-treated samples isolated from D1 males
(Figure 3C), D1 females (Figure 3D) and A2A females (Figure 3E). All data were normalized to
spinophilin abundance. All three sets had a slope greater than 1, suggesting that there was greater
abundance in the amphetamine treatment compared to the saline treatment. Of note, the D1 females
had the greatest slope (M = 2.554), suggesting the greatest increased association in this group compared
to the D1 males (M = 1.267) or A2A females (M = 1.269). Together, our data suggest that amphetamine
treatment enhances synaptic protein interactions with spinophilin across multiple sexes and cell types.
To begin to delineate amphetamine-dependent regulation of specific spinophilin interactors in
the different Cre lines, we generated a ratio of the abundance ratios from the D1 Cre animals to the
A2A Cre animals (Table S2B). As stated above, it is important to note that, given the N of 1 in the A2A
animals, these ratios are qualitative and no statistical inference can be obtained; however, these data
will inform novel lines of inquiry in future cell-specific studies. Those proteins with this ratio of ratios
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greater than 2 are shown in Table 3. No interactions with a ratio of less than 0.5 (2-fold decrease) were
detected. All ratios are shown in Table S2B.
Table 2. Spinophilin interacting proteins that had altered abundance following amphetamine treatment.
Description # PSMs Normalized AbundanceRatio (Treatment)/(Control)
Normalized Abundance Ratio
(log2): (Treatment)/(Control)
Decreased Interactions
E3 ubiquitin-protein ligase XIAP 22 0.69 −0.54
Disks large homolog 3 143 0.67 −0.58
Granulins 10 0.36 −1.47
Increased Interactions
Myelin proteolipid protein 38 2.28 1.19
Hemoglobin subunit alpha 17 2.24 1.16
ADP/ATP translocase 2 36 2.23 1.16
Clathrin light chain A 17 2.13 1.09
Adenylyl cyclase-associated protein 2 8 2.10 1.07
MCG10343, isoform CRA_b 35 2.08 1.05
Tubulin alpha-1B chain 54 2.07 1.05
Tubulin alpha chain (Fragment) 54 2.03 1.02
Cytochrome c oxidase subunit NDUFA4 13 2.03 1.02
Profilin-2 14 2.02 1.02
Reticulon (Fragment) 20 2.02 1.01
Myelin-oligodendrocyte glycoprotein 18 2.01 1.01
Serine/threonine-protein phosphatase
2A 65 kDa regulatory subunit
A alpha isoform
28 2.00 1.00
HA spinophilin was immunoprecipitated from saline and amphetamine-treated D1 Cre and A2A Cre mice.
The abundance of the individual proteins was normalized to the abundance of spinophilin. A ratio of the abundance
of proteins isolated from the amphetamine treated over the saline treated mice was generated. A subset of
spinophilin interacting proteins that had at least eight spectral counts (PSMs) and had a decreased (<0.05) or
increased (≥1.00) log2 ratio is shown. A complete list of interacting proteins (without contaminants) and their
abundance ratios are shown in Table S2A.
Table 3. Spinophilin interacting proteins that had altered abundance ratios in D1 Cre animals compared
to A2A Cre animals.
Description PSMs Female A2ARatios
Female D1
Ratios
Male D1 Avg
Ratios
Avg D1/A2A
Ratios
Endophilin-A2 12 0.50 1.38 1.28 2.63
Cofilin-1 14 1.13 4.14 1.57 2.52
Malate dehydrogenase, mitochondrial 27 0.92 3.22 1.38 2.51
Calreticulin 8 0.87 3.15 1.11 2.46
Alpha-synuclein 21 1.06 3.56 1.61 2.43
Malate dehydrogenase, cytoplasmic 41 1.05 3.59 1.38 2.36
Glutamate dehydrogenase 1, mitochondrial 23 1.05 3.58 1.39 2.36
Fructose-bisphosphate aldolase 87 1.14 3.93 1.41 2.35
Protein disulfide-isomerase A3 9 0.93 3.19 1.13 2.31
Citrate synthase, mitochondrial 32 1.37 4.58 1.55 2.24
Synapsin-1 42 1.11 3.51 1.45 2.23
Tubulin polymerization-promoting protein 9 1.08 3.24 1.56 2.23
Nucleoside diphosphate kinase 12 1.20 3.92 1.39 2.21
Fascin 26 0.89 2.78 1.13 2.20
Cytochrome b-c1 complex subunit 1,
mitochondrial 19 0.99 3.09 1.26 2.19
Carbonic anhydrase 2 14 1.22 3.75 1.54 2.18
Rab GDP dissociation inhibitor alpha 22 1.12 3.58 1.26 2.16
Protein kinase C and casein kinase
substrate in neurons protein 1 18 1.10 3.36 1.30 2.12
Endophilin-A1 23 1.11 3.37 1.33 2.12
Cytochrome c oxidase subunit 5B,
mitochondrial 13 1.17 3.52 1.43 2.12
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Table 3. Cont.
Description PSMs Female A2ARatios
Female D1
Ratios
Male D1 Avg
Ratios
Avg D1/A2A
Ratios
Adenylyl cyclase-associated protein 2 8 1.43 4.36 1.63 2.09
Cytochrome b-c1 complex subunit 2,
mitochondrial 40 1.04 3.08 1.22 2.06
Pyruvate kinase PKM 36 1.10 3.22 1.30 2.06
Profilin-2 14 1.33 3.85 1.58 2.04
Myelin proteolipid protein 38 1.58 4.56 1.89 2.04
60S ribosomal protein L17 8 1.06 3.20 1.12 2.03
40S ribosomal protein S23 11 0.89 2.40 1.23 2.03
Beta-synuclein 16 1.18 3.31 1.47 2.03
Heat shock 70 kDa protein 4 23 1.07 3.01 1.27 2.01
L-lactate dehydrogenase B chain 28 1.23 3.58 1.35 2.00
HA spinophilin was immunoprecipitated from saline and amphetamine-treated D1 Cre and A2A Cre mice.
The abundance of the individual proteins was normalized to the abundance of spinophilin. A ratio of the abundance
of proteins isolated from the amphetamine treated over the saline treated mice was generated. A second ratio
comparing the amphetamine/saline ratios identified in the 3 D1 samples and the 1 A2A sample was generated.
Those D1/A2A ratios ≥ 2.00 are shown. A complete list of interacting proteins (without contaminants) and the
cell-specific abundance ratios are shown in Table S2B.
3.4. Pathway and GO Analysis of Spinophilin Interacting Proteins Enhanced by Amphetamine
Using the DAVID Bioinformatics resource [69,70], we performed the Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway analysis on the 286 proteins that had an increased association with
spinophilin across all samples. 283 total proteins were detected from the list. A total of 94 pathways
were detected from this analysis (Table S3). 49 of the pathways were significantly enriched using a
Bonferroni adjustment (Table S3 highlighted). These include pathways associated with striatal function,
including amphetamine addiction. The top 10 pathways also include other disease states associated
with striatal dysfunction, such as Parkinson disease and Huntington disease (Table 4).
Table 4. Top 10 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with proteins
that have amphetamine-dependent increases in spinophilin.
Term Count % p Value Bonferroni
mmu01200:Carbon metabolism 27 9.54 3.52 × 10−18 7.04 × 10−16
mmu05012:Parkinson’s disease 29 10.25 2.34 × 10−17 4.69 × 10−15
mmu05016:Huntington’s disease 32 11.31 9.23 × 10−17 2.22 × 10−14
mmu00190:Oxidative phosphorylation 26 9.19 4.42 × 10−15 8.88 × 10−13
mmu04721:Synaptic vesicle cycle 19 6.71 5.04 × 10−15 9.99 × 10−13
mmu00020:Citrate cycle (TCA cycle) 15 5.30 7.94 × 10−15 1.60 × 10−12
mmu05010:Alzheimer’s disease 27 9.54 1.82 × 10−13 3.65 × 10−11
mmu01130:Biosynthesis of antibiotics 29 10.25 3.85 × 10−13 7.70 × 10−11
mmu04961:Endocrine and other
factor-regulated calcium reabsorption 15 5.30 1.92 × 10
−11 3.84 × 10−9
mmu00010:Glycolysis/Gluconeogenesis 16 5.65 5.11 × 10−11 1.02 × 10−8
The 286 proteins that had an increased association with spinophilin (log2 ratio ≥ 0.5; Table S2A) were input into the
DAVID Bioinformatics resource and analyzed using KEGG pathway analysis. The top 10 enriched pathways are
shown. All pathways are given in Table S3.
We next evaluated these increased interactions in DAVID using gene ontology terms (GO).
We evaluated Biological Processes (BP), Cellular Components (CC), and Molecular Function (MF).
We detected 247 BPs, 154 CCs, and 127 different MFs (Table S4) in the increased spinophilin interactors.
Of these, 33, 55, and 31, respectively, were significantly enriched. For BPs, we observed a large number
of metabolic processes, including ATP and NADH metabolism. We also observed vesicle trafficking
processes, including synaptic vesicle endocytosis, vesicle-mediated transport, and endocytosis.
For CCs, we observed known areas where spinophilin is enriched, including membrane, postsynaptic
density, dendrite, dendritic spine, and cytoskeleton. In addition, we matched other locations where
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spinophilin has been implicated, such as synaptic vesicle membrane [76]. For MFs, we observed known
roles for spinophilin as a scaffold, including protein binding, protein complex binding, protein kinase
binding, and actin filament binding. In addition, we observed novel putative roles for spinophilin,
including GTPase binding, ATP binding, and syntaxin-1 binding. The top 10 pathways for BP, CC,
and MF are shown in Table 5.
Table 5. Top 10 GO, BP, CC, and MF pathways associated with proteins that have amphetamine-dependent
increases in spinophilin. The 286 proteins that had an increased association with spinophilin
(log 2 ratio ≥ 0.05; Table S2A) were input into the DAVID Bioinformatics resource and analyzed using GO
BP, CC, and MF pathway analyses. The top 10 enriched pathways are shown. All pathways are given in
Table S4.
Term Count % PValue Bonferroni
Biological Process
GO:0006099~tricarboxylic acid cycle 13 4.59 3.85 × 10−15 6.78 × 10−12
GO:0006810~transport 68 24.03 1.55 × 10−12 2.70 × 10−9
GO:0006096~glycolytic process 11 3.89 8.12 × 10−11 1.42 × 10−7
GO:0006734~NADH metabolic process 8 2.83 1.11 × 10−10 1.93 × 10−7
GO:0046034~ATP metabolic process 11 3.89 2.57 × 10−10 4.48 × 10−7
GO:0015992~proton transport 12 4.24 7.90 × 10−10 1.38 × 10−6
GO:0015991~ATP hydrolysis coupled proton transport 10 3.53 8.81 × 10−10 1.54 × 10−6
GO:0050821~protein stabilization 15 5.30 7.11 × 10−9 1.24 × 10−5
GO:0015986~ATP synthesis coupled proton transport 8 2.83 2.98 × 10−8 5.20 × 10−5
GO:1904871~positive regulation of protein localization
to Cajal body 6 2.12 3.79 × 10
−8 6.61 × 10−5
Cellular Compartment
GO:0043209~myelin sheath 92 32.51 3.70 × 10−120 1.53 × 10−117
GO:0070062~extracellular exosome 159 56.18 2.16 × 10−65 8.91 × 10−63
GO:0005739~mitochondrion 88 31.10 3.66 × 10−27 1.51 × 10−24
GO:0005829~cytosol 88 31.10 4.60 × 10−26 1.90 × 10−23
GO:0005737~cytoplasm 173 61.13 3.24 × 10−22 1.34 × 10−19
GO:0016020~membrane 178 62.90 6.47 × 10−22 2.66 × 10−19
GO:0014069~postsynaptic density 32 11.31 5.02 × 10−21 2.07 × 10−18
GO:0043005~neuron projection 40 14.13 6.70 × 10−21 2.76 × 10−18
GO:0043234~protein complex 46 16.25 1.63 × 10−19 6.71 × 10−17
GO:0005743~mitochondrial inner membrane 37 13.07 2.23 × 10−19 9.20 × 10−17
Molecular Function
GO:0005515~protein binding 138 48.8 1.12 × 10−22 6.18 × 10−20
GO:0032403~protein complex binding 36 12.7 2.54 × 10−18 1.40 × 10−15
GO:0019901~protein kinase binding 36 12.7 1.24 × 10−15 6.74 × 10−13
GO:0044822~poly(A) RNA binding 55 19.4 4.52 × 10−14 2.49 × 10−11
GO:0000166~nucleotide binding 74 26.1 2.72 × 10−13 1.50 × 10−10
GO:0019904~protein domain specific binding 27 9.5 5.67 × 10−13 3.13 × 10−10
GO:0098641~cadherin binding involved in cell-cell adhesion 26 9.2 1.77 × 10−12 9.79 × 10−10
GO:0008022~protein C-terminus binding 22 7.8 1.30 × 10−11 7.15 × 10−9
GO:0005516~calmodulin binding 19 6.7 5.09 × 10−10 2.81 × 10−7
GO:0003779~actin binding 25 8.8 6.35 × 10−10 3.51 × 10−7
3.5. Interactome Analysis of Spinophilin Interacting Proteins Enhanced by Amphetamine
We next wanted to organize spinophilin interacting proteins that were enhanced by amphetamine
based on interactions and functional classifications. To do this, we utilized the string-db program [77,78].
This allows for the pictorial representation of proteins and their interactions. To reduce the complexity
of the submitted proteins, we used a high stringency confidence score (0.900) and removed any proteins
that were not connected. We next grouped proteins into 12 categories based on known function and
these interactions (Figure 4). These categories are: Metabolism, ATPases, vesicle trafficking, synaptic
signaling, cytoskeleton, ribosomal and nuclear, scaffolding, heatshock, G-proteins and GTPases,
semaphorin signaling, BBSome, and other.
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Figure 4. Graphical representation of interactors input into the string-db from protein complexes that
had greater abundance in the HA immunoprecipitates isolated from amphetamine-treated animals.
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function. To reduce the complexity of this map, only those proteins that had at least 1 interaction at a
confidence of 0.9 (highest confidence).
3.6. Alteration and Validation of Novel Spinophilin Interacting Proteins
While some of the proteins isolated using the HA spinophilin antibody are known spinophilin
interactors (e.g., PP1, glutamate receptors, actin), some have not been previously validated. Therefore,
we wanted to validate some of the proteins that had an altered association with spinophilin that
are involved in different processes. We chose SAP102 (Dlg3), src kinase inhibitor protein 1 (Srcin1),
and clathrin heavy chain (Cltc) as proteins involved in synaptic scaffolding, signaling, and vesicle
trafficking, respectively. To determine if these proteins interact with spinophilin in a specific manner,
we dissected out total (dorsal and ventral (e.g., accumbens)) striatum (Str) and olfactory tubercle
(OT), a further ventral portion of the striatum from wildtype and whole-body spinophilin KO
animals. We chose these regions based on their roles in psychostimulant sensitization [31–33].
We immunoprecipitated striatal and tubercle lysates with a spinophilin antibody and immunoblotted
for spinophilin, SAP102, Srcin1, and clathrin heavy chain. Spinophilin was only detected in WT and
not KO samples (Figure 5). Moreover, spinophilin interactions were only detected in WT and not KO
animals. These data suggest that these proteins are specific interactors with spinophilin.
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4. Discussion 
4.1. Spinophilin Functional Localization 
Spinophilin is a highly abundant spine-enriched protein. We have previously found that loss of 
spinophilin modulates striatal behaviors. Specifically, loss of spinophilin decreases motor 
performance and motor learning on a rotarod apparatus [66]. Moreover, we previously reported that 
spinophilin KO mice, in contrast to WT mice, do not undergo amphetamine-induced locomotor 
sensitization [63]. In addition, others have observed alterations in the response of spinophilin KO 
mice in rotarod behaviors and following cocaine treatment [79,80]. Together, these data suggest that 
spinophilin is important in striatal based behaviors. However, how spinophilin contributes to these 
behaviors is unclear. As the major postsynaptic density-enriched PP1-interacting protein, 
spinophilin’s functional regulation of the above striatal behaviors may be due to its targeting of PP1 
to synaptic proteins. Moreover, while spinophilin, as its name implies, is enriched in dendritic spines, 
it is also present in dendrites, presynaptic terminals, and glial cells [54,55]. Therefore, spinophilin 
may have functions beyond just dendritic spines. 
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STR OT STR OT
Figure 5. Validation of spinophilin interactions. WT or spinophilin KO striatal (STR) or olfactory tubercle
(OT) lysates were immunoprecipitated with a spinophilin antibody. Lysates or immunoprecipitates
were immunoblotted for spinophilin and three interacting proteins that were detected in the
HA immunoprecipitates that had a decreased (SAP102) or increased (Clathrin heavy chain and
SRCIN1) interaction with spinophilin in amphetamine-treated animals. Spinophilin and all associated
proteins were detected in the spinophilin immunoprecipitates from WT animals, but were absent in
immunoprecipitates isolated from KO animals.
4. Discussion
4.1. Spinophilin Functional Localization
Spinophilin is a highly abundant spine-enriched protein. We have previously found that loss of
spinophilin modulates striatal behaviors. Specifically, loss of spinophilin decreases motor performance
and motor learning on a rotarod apparatus [66]. Moreover, we previously reported that spinophilin
KO mice, in contrast to WT mice, do not undergo amphetamine-induced locomotor sensitization [63].
In addition, others have observed alterations in the response of spinophilin KO mice in rotarod
behaviors and following cocaine treatment [79,80]. Together, these data suggest that spinophilin is
i portant in striatal based behaviors. However, how spinophilin contributes to these behaviors is
unclear. As the ajor postsynaptic density-enriched PP1-interacting protein, spinophilin’s functional
regulation of the above striatal behaviors may be due to its targeting of PP1 to synaptic proteins.
Moreover, while spinophilin, as its name implies, is enriched in dendritic spines, it is also present in
dendrites, presynaptic terminals, and glial cells [54,55]. Therefore, spinophilin may have functions
beyond just dendritic spines.
4.2. Regulation of the Spinophilin Interactome Following Amphetamine Treatment
To begin to identify cell-type specific spinophilin interactions that may be important in behavioral
changes observed following psychostimulant abuse, we created mice that Cre-dependently overexpress
an epitope-tagged (HA) form of human spinophilin. Using HA immunoprecipitation from different
cell types and TMT labeling, we probed the spinophilin interactome in the striatum of saline
compared to amphetamine treated animals. As previously observed in rats [58,59], the amount
of spinophilin detected (based on labeled peptide abundance) was increased following amphetamine
treatment. Interestingly, across all samples the abundance of the different proteins was greater in the
amphetamine-treated compared to the control treated lysates, even when normalizing to the increased
spinophilin expression. This is in contrast to what we observed previously in DA-depleted striatum
(an animal model of Parkinson disease) [62]. In that previous study, 60 proteins were decreased
whereas 31 total proteins were increased across two different fractions. In contrast, in the current
study, we only observed three proteins that were decreased and 286 proteins that were increased
following amphetamine treatment. These data suggest that spinophilin interactions are decreased
by DA depletion and increased by hyperdopaminergic signaling. However, it is critical to note that
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while specific, there are low levels of expression of the HA-tagged, human spinophilin and while we
validated expression of the HA-tagged form of the human protein by WB and MS/MS, as well as
the interactor, PP1, additional interacting proteins may be non-specifically interacting with the beads.
Therefore, future studies will need to follow-up on these studies to delineate those interactions that are
real and that are modulated by amphetamine.
Regulation of DA leads to alterations in striatal medium spiny neuron spine density. Specifically,
loss of DA decreases spine density [81–83] and psychostimulant treatment increases spine density [84,85].
Spinophilin is also known to regulate spine density, with acute knockdown of spinophilin decreasing
spine density in hippocampal cultures [86]. Whole-body spinophilin KO animals do not have loss of
dendritic spines in adulthood (and have a paradoxical increase in young animals) [56]. This lack of
an effect may be due to compensatory changes, such as decreases in expression of PP1 [80]. However,
data showing amphetamine-dependent increases in spinophilin expression [58,59] and our data showing
a lack of amphetamine-dependent locomotor sensitization [66] and the data presented in this paper
may suggest that changes in the spinophilin expression and/or interactions are critical for normal
psychostimulant-induced behaviors. However, it is currently unclear if amphetamine-induced increases
in spine density are also abrogated or modulated in spinophilin KO mice.
4.3. Classes and Specific Spinophilin Protein Interactions that are Modulated by Amphetamine
Using GO and KEGG analysis along with hand annotation of altered interactions in string-db we
detailed different classes of spinophilin interacting proteins that have an increased interaction with
amphetamine. These protein classes co-purify with spinophilin, including cytoskeletal and vesicle
trafficking proteins [62,73,87,88]. Moreover, many of the pathways identified associate with protein
binding, striatal function and diseases, and synaptic/postsynaptic protein organization. In addition
to these known functions of spinophilin and striatum-dependent regulation by amphetamine,
we observed novel/less well-characterized spinophilin interactions. Some of these may be non-specific.
For instance, myelin sheath was one of the most abundant cellular components. Myelin sheath
components may be non-specifically sticky and may not be specific interactions. Indeed, myelin
sheath components are associated with the CRAPome [89], a list of non-specific interactions that may
non-specifically co-precipitate. However, even though some of these interactions may be non-specific,
these pathways may be regulated by amphetamines. For instance, psychostimulant abuse in humans
may be associated with altered neuron myelination [90]. Therefore, while additional studies will need
to detail specific spinophilin interactions, our data may delineate alterations in protein expression
following amphetamine treatment.
Another major class of altered spinophilin interacting proteins were vesicle trafficking proteins.
For instance, the synaptic vesicle cycle was identified as being enriched in the KEGG pathway and
we delineated multiple vesicle trafficking proteins. While not much is known about the role of
spinophilin in vesicle trafficking, one study has detailed spinophilin as a regulator of presynaptic
vesicle function [76]. We also validated a vesicle trafficking protein, clathrin heavy chain, as a specific
interactor with spinophilin. Spinophilin may play a role in vesicle trafficking on glutamatergic
(or dopaminergic) presynaptic terminals or postsynaptic MSNs; however, given the enrichment of
endogenous spinophilin in spines and a lack of detected presynaptic vesicle proteins (e.g., syntaxin,
SNAP-25, synaptobrevin, etc.), we posit that this role is more postsynaptic; however, we cannot rule
out a presynaptic role for spinophilin in striatum.
We observed many metabolic proteins, including lactate and succinate dehydrogenases, and
ATPases, that were increased in spinophilin immunoprecipitates following amphetamine treatment.
Moreover, some of the pathways with altered protein expression included glycolytic process, ATP
metabolism/hydrolysis/synthesis, tricarboxylic acid cycle, and Citrate (TCA) cycle. Spinophilin has
been shown to associate with and regulate the membrane localization of the Na+-K+-ATPase [91].
Moreover, amphetamines may modify the activity of the Kreb’s cycle [92,93]. However, how
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alterations in spinophilin interactions with metabolic proteins modulate response to amphetamines is
an unexplored area.
4.4. Direct and Indirect Pathway Striatal MSNs and Spinophilin Interactions
By using mice expressing spinophilin Cre dependently, we were able to isolate complexes from
dMSNs and iMSNs. We used a D1 DA receptor Cre line and an A2A adenosine receptor Cre line.
These Cre lines were created as part of the GENSAT project [64,65]. While D1 and A2A are enriched
in striatal MSNs, there may be expression in other cell types and other brain regions. We observed
some HA spinophilin expression in other brain regions, including the hippocampus and prefrontal
cortex (data not shown). While these Cre lines only minimally express in these other regions, it may be
sufficient for driving expression of the HA spinophilin.
Previous studies have observed persistent psychostimulant-dependent increases in spinophilin
density in dMSNs (months), whereas in iMSNs these changes are more transient (days) [84]. We found
that there was a greater association of spinophilin with multiple proteins 72 h following amphetamine
treatment and that this occurred in both Cre-driver lines. This suggests that amphetamine may be
regulating interactions in both cell types. While our preliminary study suggests the level of increase
was greater overall in the dMSNs compared to the iMSNs, it is unclear if these changes will persist in
both populations and future studies will need to evaluate the persistence of these changes and the link
between spinophilin and modulation of dendritic spine density.
While most protein interaction changes were similar in the two cell types, the magnitude
of the effect was different between the different cell types. However, there was a cell-specific
effect of amphetamine treatment in two proteins that are known to be involved in striatal
pathologies. We detected both α-synuclein (SNCA) and tau (MAPT) proteins in the HA-spinophilin
immunoprecipitates. While additional work needs to determine if endogenous spinophilin associates
with these proteins, it was interesting that amphetamine increased the association of spinophilin with
both of these proteins, but this increase was only in the D1 Cre containing animals. These proteins
were enriched 2.45-fold (α-synuclein) and 1.85-fold (Tau) in the dMSNs compared to the iMSNs.
These proteins play major roles in PD and AD, respectively, and amphetamine is known to increase
α-synuclein and tau protein levels [94,95]. Moreover, phosphorylation of these proteins is important in
modulating their function and aggregation potential, but if spinophilin plays a role in modulating this
aggregation has, to our knowledge, not been evaluated.
5. Conclusions
Our data identify novel putative spinophilin interactions that are modulated by amphetamine.
As a whole, amphetamine increased spinophilin expression and enhanced spinophilin interactions.
While these changes occur in both MSN cell types, this preliminary study suggests dMSNs appear
to be more influenced by amphetamine. Future studies need to validate these interactions, use
additional approaches to enhance cell specific expression and interactions (e.g., viral transduction
of Cre-dependent epitope tagged spinophilin), and evaluate long-term amphetamine changes
(e.g., 1-month) in the different striatal MSN subtypes. However, the current proteomics study
is the first to outline potential pathways of spinophilin interactors that are modulated by
amphetamine. Moreover, we have begun to uncover differences in amphetamine-dependent
spinophilin interactions in the different striatal cell types. This knowledge will enhance our
understanding of amphetamine-dependent regulation of cell-specific striatal biology.
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